-

Theraclion: Monthly Information on the Total Number of Voting Rights and Shares Comprising the Share Capital

Article 223-16 du Règlement Général de l’Autorité des marchés financiers

MALAKOFF, France--(BUSINESS WIRE)--Regulatory News:

Theraclion (Paris:ALTHE):

Listed on Euronext Growth Paris
PEA PME eligible
ISIN Code : FR0010120402
Website : www.theraclion.com

Voting rights :

Date

Total number of shares of Theraclion

Total number of theoretical voting rights of Theraclion (1)

Total number of real voting rights of Theraclion (2)

31/05/2026

73 123 311

89 143 355

87 584 876

(1) Theoretical voting rights are calculated on the basis of all shares to which voting rights are attached, including shares stripped of voting rights, in accordance with Article 223-11 of the AMF's General Regulation
(2) Actual voting rights correspond to the total number of voting rights exercisable at the Annual General Meeting. They are calculated on the basis of the total number of voting rights attached to the total number of shares less shares stripped of voting rights.

About Theraclion

Theraclion is a French MedTech company developing a non-invasive alternative to surgery through the innovative use of focused ultrasound.
High-Intensity Focused Ultrasound (HIFU) does not require incisions or an operating room, leaves no scars, and allows patients to resume normal activities immediately. HIFU concentrates therapeutic ultrasound on an internal focal point from outside the body.
Theraclion is developing Sonovein®, a robotic HIFU platform for varicose vein treatment, CE marked under the MDR (EU 2017/745), with the potential to replace millions of surgical procedures each year. To date, Sonovein® has been adopted by more than a dozen centers worldwide and used in over 4,000 procedures. In the U.S., Sonovein® is not yet available for sale.
Based in Malakoff (Paris), Theraclion’s team comprises around 35 people.

For more information, please visit www.theraclion.com and follow the LinkedIn account.
Theraclion is listed on Euronext Growth Paris Eligible for the PEA-PME scheme
Ticker: ALTHE - ISIN Code: FR0010120402 LEI: 9695007X7HA7A1GCYD29

Contacts

Theraclion
Martin Deterre
Chief Executive Officer
investors@theraclion.com

Theraclion

BOURSE:ALTHE
Release Versions
EnglishFrench

Contacts

Theraclion
Martin Deterre
Chief Executive Officer
investors@theraclion.com

More News From Theraclion

Theraclion Announces First Clinical Deployment of Sonovein® in Hainan, China

MALAKOFF, France--(BUSINESS WIRE)--Regulatory News: THERACLION (ISIN: FR0010120402 – Mnemo: ALTHE), an innovative company developing a robotic platform for non-invasive therapy using high intensity focused ultrasound (HIFU) for the treatment of varicose veins, announces a significant milestone in its China expansion strategy with the deployment of a SONOVEIN® system at Boao Super Hospital in Hainan Province supported by its Joint Venture with its strategic partner Inner Mongolia Furui Medical S...

Theraclion Announces the Success of the First International HIFU Congress in Parma, Where Promising Preliminary Results From Its Sonovein® SpeedPulse Were Presented

MALAKOFF, France--(BUSINESS WIRE)--Regulatory News: Theraclion (ISIN: FR0010120402; Ticker: ALTHE), an innovative company developing a robotic platform for non-invasive therapy using high intensity focused ultrasound (HIFU) for the treatment of varicose veins (the “Company”), announces the success of the first international HIFU congress, held in Parma on May 22 and 23, 2026, during which promising preliminary results from the clinical study conducted in Prague with its next-generation Sonovein...

Theraclion Announces the Strong Success of Its Oversubscribed Capital Increase

MALAKOFF, France--(BUSINESS WIRE)--Regulatory News: This press release and the information it contains must not be distributed, directly or indirectly, in the United States, Canada, Japan or Australia. Theraclion (ISIN: FR0010120402; Ticker: ALTHE), an innovative company developing a robotic platform for non‑invasive therapy using high‑intensity focused ultrasound (HIFU) for the treatment of varicose veins (the “Company”), announces the strong success of its € 5,992,544.16 capital increase with...
Back to Newsroom